Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $29.40, for a total transaction of $349,301.40. Following the completion of the transaction, the chief operating officer directly owned 377,802 shares in the company, valued at $11,107,378.80. This represents a 3.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Friday, November 13th, Julie Rubinstein sold 11,466 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.93, for a total transaction of $331,711.38.
- On Monday, November 9th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $30.12, for a total transaction of $357,855.72.
- On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.53, for a total transaction of $315,202.93.
- On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total transaction of $317,579.13.
- On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total value of $302,609.07.
- On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total value of $338,014.45.
- On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
- On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
- On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
- On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.41, for a total value of $301,896.21.
Adaptive Biotechnologies Trading Down 1.5%
Shares of NASDAQ ADPT traded down $0.44 during mid-day trading on Friday, hitting $29.04. 2,063,725 shares of the company traded hands, compared to its average volume of 2,197,728. The company has a quick ratio of 3.87, a current ratio of 3.97 and a debt-to-equity ratio of 1.82. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $32.21. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of -64.53 and a beta of 2.18. The business has a 50 day moving average of $26.91 and a two-hundred day moving average of $20.13.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative return on equity of 23.95% and a negative net margin of 23.67%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $71.57 million. During the same quarter in the previous year, the company earned $0.06 EPS. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.24 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Adaptive Biotechnologies
Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Adaptive Biotechnologies in the second quarter worth about $324,735,000. Wellington Management Group LLP grew its stake in shares of Adaptive Biotechnologies by 53.2% during the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after purchasing an additional 2,053,944 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $37,109,000. Freestone Grove Partners LP acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at approximately $18,912,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at approximately $16,858,000. Institutional investors own 99.17% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on ADPT shares. Piper Sandler lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group started coverage on Adaptive Biotechnologies in a report on Tuesday, September 29th. They issued a “buy” rating and a $35.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. TD Cowen lifted their price target on Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.31.
Read Our Latest Report on ADPT
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
